Evaluation of the Diagnostic and Prognostic Value of Immunohistochemical Markers in Precancerous Lesions of the Cervix
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Feb 26, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on studying certain proteins in tissue samples from women who have precancerous lesions of the cervix, known as CIN or SIL. The goal is to understand how these proteins can help doctors diagnose these lesions and predict whether they might develop into cervical cancer in the future. The trial is not yet recruiting participants, but when it begins, it will be looking for women aged 18 and older who have been diagnosed with CIN/SIL and have had a cervical biopsy. Participants will need to give their written consent to use their tissue samples for this research.
If you join this study, you can expect that your previously collected tissue samples will be analyzed for specific markers. This research could lead to better ways to identify and manage precancerous conditions of the cervix. It’s important to note that there are no exclusion criteria, meaning if you meet the age and diagnosis requirements, you may be eligible to participate. This study could contribute valuable information that helps improve cervical cancer screening and treatment in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients with a diagnosis of CIN/SIL undergoing cervical biopsy/concussion whose tissue sample is archived at the Operative Unit of Pathological Anatomy and Histology
- • Obtaining written informed consent for the use of biological samples
- • Patients aged 18 years and over
- • Exclusion Criteria: none
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Paolo Casadio, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported